Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 154Cyclophosphamide 116fludarabine phosphate 109fludarabine 68Mycophenolic Acid 62Whole-Body Irradiation 56ibrutinib 46Tacrolimus 46Peripheral Blood Stem Cell Transplantation 44Lenalidomide 43Cyclosporine 36Busulfan 35Bendamustine Hydrochloride 34Antilymphocyte Serum 31ofatumumab 30obinutuzumab 28Melphalan 28idelalisib 26Alemtuzumab 26Filgrastim 25Methotrexate 23venetoclax 22Chlorambucil 21Granulocyte Colony-Stimulating Factor 20acalabrutinib 19thymoglobulin 18Cyclosporins 16Sirolimus 15Etoposide 15Pentostatin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Lymphocytic, Chronic, B-Cell × beta-Glucans × Clear all
NCT00290407 2018-05-04

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

University of Louisville

Phase 2 Terminated
2 enrolled 2 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡